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Controlled Trial of Desmopressin in Liver Cirrhosis and Other Conditions
Associated With a Prolonged Bleeding Time
By Pier Mannuccio Mannucci, Vicente Vicente, Luciana Vianello, Marco Cattaneo, lgnacio Alberca,
Maria Piera Coccato, Elena Faioni, and Daniela Man
The synthetic vasopressin derivative desmopressin
(DDAVP) shortens a prolonged bleeding time (BT) in
patients with uremia, congenital platelet dysfunction, and
von Willebrand disease. To establish the limits of the
clinical usefulness of DDAVP, a controlled randomized
study was carried out in 53 patients and ten volunteers
with different conditions that have in common a prolonged
BT. DDAVP significantly shortened the BT in 21 cirrhotics
(P < .01 ), in eight patients with unclassified prolonged BT
(P < .05) and in ten volunteers taking the antiplatelet
drugs aspirin (P < .05) and ticlopidine. The BT changes
R ECENT STUDIES have shown that the synthetic vaso-
pressin derivative desmopressin (DDAVP) shortens
the prolonged bleeding times (BT) associated with a variety
of clinical disorders of primary hemostasis. In von Wille-
brand disease, the most common congenital cause of pro-
longed BT, the effectiveness of DDAVP is clearly explained
by the fact that the prolonged BT is due to low or abnormal
plasma von Willebrand factor (vWF), the most important
determinant of platelet adhesion to the damaged vessel wall.5
By releasing autologous vWF from storage sites (possibly the
endothelial cells), DDAVP transiently normalizes vWF 1ev-
els and shortens the BT, at least in patients with vWF that is
functionally normal.’ However, DDAVP also shortens the
BT in such conditions as uremia2’3 and congenital and
acquired platelet dysfunctions,4 in which no quantitative or
qualitative vWF abnormality has been convincingly demon-
strated. These observations, together with a recent in vitro
study demonstrating a local hemostatic effect of the drug on
the vessel wall,6 led us to postulate that DDAVP might have
broader clinical usefulness as a primary hemostatic agent in
patients with prolonged BT due to causes other than low or
dysfunctional vWF. To establish the limits of the clinical
usefulness of DDAVP, we have carried out a controlled study
in 53 patients with different clinical conditions that have a
prolonged BT in common, and in ten volunteers taking the
antiplatelet drugs aspirin or ticlopidine.
MATERIALS AND METHODS
Patients. Fifty-three patients (25 men and 28 women, with a
median age of 37 years; range, 15 to 65) seen at the A. Bianchi
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were not statistically significant in 1 5 patients with severe
thrombocytopenia nor in nine with congenital platelet
dysfunction, even though a few patients with storage pool
deficiency responded with a marked BT shortening. Our
findings indicate that DDAVP might be given when biopsies
or other surgical procedures must be carried out in
patients with prolonged BT. However, the compound is
often ineffective in patients with thrombocytopenia or
congenital platelet dysfunction.
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Bonomi Hemophilia and Thrombosis Center in Milan, Italy, or at
the Department of Hematology in Salamanca, Spain, were admitted
to the study on the basis of a BT of ten minutes or longer when
measured before the first experimental treatment (see below). Even
though the upper normal BT limit is seven minutes at both centers,
an admission limit of ten minutes was chosen because we consider
this value to be the clinical threshold between normal and abnormal
hemostasis. Of the 53 patients admitted to the study, 21 had
alcoholic or postnecrotic liver cirrhosis, diagnosed by liver tests and
biopsy. Their platelet counts were normal or moderately low (me-
dian, 106 x 109/L; range, 45 to 286). Fifteen patients had severe
thrombocytopenia (median platelet count, 13 x 109/L; range, I to
53), due to increased platelet destruction by autoantibodies in five
cases and due to decreased bone marrow production in ten cases
(seven had aplasia, one familial thrombocytopenia, one myeloma,
one chronic lymphocytic leukemia). Nine patients belonging to
different kindreds had congenital platelet dysfunction, diagnosed as
delta storage pool deficiency in seven and Glanzmann thrombasthe-
nia in two cases, according to previously described criteria.7” Finally,
eight patients had prolonged BT associated with lifelong histories of
bleeding but with normal platelet counts, no laboratory evidence of
von Willebrand’s disease, no defect in platelet aggregation on
secretion, no storage pool deficiency, non any underlying condition
known to be associated with a prolonged BT. These unexplained
prolonged BT might be due to vascular defects or to as yet
unidentified platelet dysfunctions. We have called this patient group
“unclassified prolonged BT.” None of the patients had taken aspirin
on other drugs that affect platelet behavior for at least ten days
before the study.
We also studied six volunteers who had borderline on slightly
prolonged BT due to the ingestion of 500 mg aspirin two hours before
the study, and four volunteers who had very prolonged BT because
they had taken a daily dose (500 mg) of the antiplatelet drug
ticlopidine for six days before the study. Ticlopidine is a potent
antiplatelet agent, available in Europe and presently under clinical
trials in the United States and in Canada, which markedly prolongs
the BT through a presently unknown mechanism.9 All the patients
and volunteers were aware of the nature and the purpose of the
study, and all gave informed consent according to the Declaration of
Helsinki.
Design of the study. Patients and volunteers were randomly
assigned to a single infusion of DDAVP (Valeas, Milan, Italy) or of
saline, and each of them was crossed oven from one treatment to the
other after 20 days. After a nest period of at least 30 minutes, 0.3 zg
of DDAVP per kilogram body weight was added to 50 mL of
physiological saline and infused over a period of 30 minutes;
physiological saline alone was infused in the same way. The study
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Figures indicate median values and, in parentheses. ranges. Asterisks indicate significance of difference between post-DDAVP or -saline values and
baseline values (P < .05,  #{149},C)< 0 1 ). Significance was not evaluated for the ticlopidine group because of the small number of patients.
could not be performed on a double-blind basis because DDAVP
infusion can be detected by an accompanying mild facial flushing.
Blood samples were collected and plasma prepared as previously
described.’
Laboratory methods. The tests were performed in Milan and
Salamanca with the same reagents, methods, and standards, except
that vWF multimeric analysis was done in Milan on plasma samples
kept frozen at - 70 #{176}Cand transported in dry ice. All tests were
carried out on blood drawn before the infusion of DDAVP or saline
(time 0), immediately after the infusion (time 30), and four hours
after the infusion had been started (time 240).
Bleeding times were obtained with the Simplate II device (Gen-
eral Diagnostics, Milan, Italy). Results were expressed as the
average BT from the two vertical incisions. In both laboratories, the
range of normal with this method was three to seven minutes.
Platelets were counted by phase-contrast microscopy. The pnothrom-
bin time (PT) was determined by using the Manchester Compana-
tive Reagent (overseas version, Laboratoni Baldacci, Pisa, Italy),
and the activated partial thromboplastin time (APTT), with a
commercial reagent (Automated P11’, General Diagnostics). Values
of both the coagulation screening tests were expressed as ratios of
patient to pooled normal plasma (obtained from 15 healthy women
and 15 healthy men). Factor VIII (FVIII) was assayed by a
one-stage clotting method based on the APTT.” vWF antigen
(vWF:Ag) was assayed by quantitative immunoelectnophonesis,
using a commercial monospecific antiserum (Istituto Behning, Sco-
pitto, Aquila).’ Ristocetin cofacton (RiCof) was assayed with
formalin-fixed platelets.” FVIII, vWF:Ag, and RiCof were
expressed in units per deciliter, with reference to pooled normal
plasma calibrated against the First International Plasma Standard
for Factor Vill-related Activities (National Institute for Biological
Standards, London). vWF multimers were analyzed by agarose
electrophoresis in the presence of sodium dodecyl sulfate (SDS), as
previously described.’
Statistical analysis. The BT values were not normally distrib-
uted, and there were BT that did not stop after 30 minutes and were
recorded as longer than 30 minutes. Hence BT values before and
after DDAVP on placebo were expressed as medians and ranges. The
other measurements were normally distributed, and thus were
expressed as means ± SD. Correlation coefficients were calculated
either by the Speanman rho test or as linear correlation coefficients
(r).
RESULTS
An overall picture of the BT (given as medians and
ranges) before and after DDAVP or saline in the patient and
volunteer groups is given in Table 1 . The two median BT
obtained before either treatment (time 0) did not differ
significantly in any of the groups.
In patients with liver cirrhosis, the prolongation of the
baseline BT was unrelated to the platelet count (Fig 1) (no
platelet function tests were performed). At 30 and 240
minutes after DDAVP, the median BT was significantly
shorter than at time 0 (P < .01, Table 1). In nine of 21
patients at time 30 and in two at time 240, the BT had
become shorter than ten minutes, the limit for admission to
the study. Responses or non-responses to DDAVP occurred
irrespective of the baseline platelet count. After saline, the
median BT had not changed significantly at time 30 and at
time 240 (Table 1). The BT shortened to less than ten
minutes in two patients at time 30 and in five at time 240
(Fig I ). In patients with unclassified prolonged BT, the
median BT became significantly shorter after DDAVP
(P < .05 Table I ); in four of eight patients BT became
shorter than ten minutes at time 30 and in three at time 240,
but in none after saline (Fig 2).
In patients with thrombocytopenia, there was no signifi-
cant change in the BT after either saline or DDAVP (Table
1 ), and the BT was shortened to less than ten minutes in only
one case after saline. In the two patients with Glanzmann
thrombasthenia, the baseline BT was longer than 30 minutes
and remained so at all times after DDAVP or saline. In the
seven patients with congenital storage pool deficiency, the
median BT did not significantly change after DDAVP or
saline (Table 1). After DDAVP, the BT became shorter than
ten minutes in two patients at time 30 and in one at time 240,
but in none after saline (Fig 3).
Table 1 . Bleedin g Times Before an d After DDAVP o r Saline Infusion in Patients With Pr olonged Bleeding Times
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Time 0 (30 mm (4 h Time 0 (30 mm (4 h
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In the six volunteers who took aspirin the median BT was
significantly shortened at times 30 and 240 after DDAVP
(P < 0.05) but not after saline (Table 1 and Fig 4). Facial
flushing occurred in all cases after DDAVP, whether or not
they had taken aspirin. In all four volunteers who took
ticlopidine, whose baseline BT were longer than those taking
aspirin (Fig 4), the BT had shortened to less than ten minutes
at time 30 after DDAVP but had returned to the prolonged
values in three at time 240. At no time after saline did the BT
shorten to ten minutes or less. Flushing occurred in all cases
after DDAVP, whether or not they had taken ticlopidine.
These data were not statistically analyzed because of the
small number of patients.
After DDAVP or saline, all measurements other than the
BT behaved in the same way in each patient or volunteer
group. Hence the values for all groups were pooled and
analyzed together (Table 2). After DDAVP, there were
significant increases in FVIII, vWF:Ag, RiCof(P < .001) at
times 30 and 240; shortening of the APTT, expressed by a
lower ratio (P < .001), at times 30 and 240; slight prolonga-
tion of the PT expressed by a higher ratio (P < .01) at times
30 and 240; and no significant change in the platelet counts.
No significant change in any of these was seen after saline.
Correlations between the DDAVP-induced changes (differ-
ences between pretreatment and posttreatment values) in BT
and in other measurements were calculated both for each
patient group and for all the groups considered as a whole.
No significant correlations were found (data not shown).
The multimeric structure of vWF before and after
DDAVP was studied in at least two patients in each group,
comparing, when available, one patient in whom the BT
became shorter than ten minutes and another in whom it did
not. Before DDAVP, the multimeric structure in the
patients’ plasma was no different from that observed in
normal plasma. After DDAVP, larger vWF multimers than
those present in pretreatment plasma appeared at time 30 in
all patients, whether or not the BT became shorter (Fig 5).
There were no changes in the multimeric structure when the
patients were treated with saline.
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Fig 4. Changes in bleeding times in six volunteers taking 500
mg aspirin (open circles) and in four volunteers taking 500 mg
ticlopidine (solid circles).
1150 MANNUCCI ET AL
Fig 2. Changes in bleeding times in eight patients with unclas-
sifled prolonged bleeding time.
A TIME (mln) B TIME (mm)
Fig 1 . Changes in bleeding times before (time 0). immediately
after (time 30), and 4 hours after (time 240) infusion of DDAVP
(left panel) or saline (right panel) in 21 patients with liver cirrhosis.
Patients with baseline platelet counts higher than 1 00 x 1 O’/ I are
indicated by open circles; patients with platelet counts lower than
100 x 1O’/L. by solid circles. The dashed horizontal line indicates a
bleeding time of 1 0 minutes, the value for admission to the trial.
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Fig 3. Changes in bleeding times in seven patients with delta
storage pool deficiency.
vWF:Ag
(U/dL)
RiCof
(U/dL)
Table 2. Laboratory Measurements Before and After DDAVP or Saline Infusion
DDAVP Saline
Time 30 Time 240 Time 30 Time 240
Time 0 (30 mm (4 h Time 0 (30 mm (4 h
(Before After After (Before After After
Infusion) Infusion) Infusion) Infusion) Infusion) Infusion)
151 ± 59
1.10 ± 0.14
1.11 ± 0.25
255 ± 69
1.13 ± 0.15
1.02 ± 0.26
252 ± 137 291 ± 112 339 ± 126 247 ± 129 247 ± 123 249 ± 126
215 ± 168 267 ± 150 312 ± 169 220 ± 172 213 ± 160 216 ± 164
F VIII
(U/dL)
PT ratio
APTT ratio
Platelet count
(x 109/L) 143 ± 122 138 ± 117 140 ± 129 143 ± 116 140 ± 114 152 ± 122
Figures indicate means ± SD. Asterisks indicate significance of differences between post-DDAVP or -saline values and baseline values: #{149}P < .01;
310 ± 140
1.13 ± 0.15
1.00 ± 0.25
146 ± 62
1.09 ± 0.12
1.11 ± 0.25
143 ± 60
1.10 ± 0.12
1.12 ± 0.26
147 ± 58
1.09 ± 0.12
1.10 ± 0.24
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#{149}#{149}#{149}P< .001 (ttest for pained samples).
DISCUSSION
The purpose of this controlled study was to see whether or
not DDAVP is effective in a number of clinical situations
that all have prolonged BT, the best available laboratory
indication ofabnormal primary hemostasis. The most signifi-
cant finding was that after DDAVP, the BT became less
than ten minutes in about half of the cirrhotic patients. This
is the value we consider the upper clinical threshold for
normal primary hemostasis. DDAVP was also effective in
patients with unclassified prolonged BT and in volunteers
taking the antiplatelet drugs aspirin and ticlopidine, whereas
the shortening of the BT was not significant in severe
thrombocytopenia or in congenital platelet dysfunction, even
though three of seven patients with congenital storage pool
Fig 5. Autoradiograph pattern of plasma vWF electrophores-
ed in 1 .4% high-gelling temperature agarose in the presence of
SDS and detected by ‘251-labeled affinity-purified antibody. The
arrow indicates the origin of the running gel and the anode is at the
bottom of the gel. From left to right: normal plasma; plasma from a
patient with liver cirrhosis before (bleeding time: 21 minutes) and
30 minutes after (bleeding time: 9 minutes) DDAVP; plasma from
another patient with liver cirrhosis before (bleeding time: 20
minutes) and 30 minutes after (bleeding time: 20 minutes) DDAVP.
The brackets indicate the large vWF multimers that appear in both
plasma after DDAVP.
deficiency responded to DDAVP with a marked BT short-
ening.
Why the BT is prolonged in cirrhotics is not completely
understood.’#{176}” Mild or moderately severe thrombocytopenia
is usually present in cirrhosis and was also found in our
patients, but their platelet counts were not negatively corre-
lated with their BT. An abnormal vWF is also unlikely
because patients had normal or high baseline levels of
vWF:Ag and RiCof and the multimeric structure of vWF in
their plasma did not differ from that of healthy subjects.
Notwithstanding the present uncertainty about the causes of
prolonged BT in cirrhotics, the shortening of the BT induced
in about half of our patients by DDAVP indicates that this
drug might be given when liver biopsies or other surgical
procedures would be otherwise contraindicated by a pro-
longed BT. It must be emphasized, however, that the hemo-
static derangement of liver disease is complex, and that the
modest and short-lived shortening of the BT seen in most of
the responders may not be sufficient to significantly reduce
the clinical risk of hemorrhage. The APTT shortened after
DDAVP but, at variance with others,’2 we have seen no
shortening of the prothrombin time. Hence the hemostatic
derangement of liver disease is not completely corrected by
DDAVP, and only clinical experience will establish the
hemostatic efficacy of the compound.
DDAVP also shortened the prolonged BT induced by the
antiplatelet drugs ticlopidine and aspirin, the latter observa-
tion being in agreement with that made by Kobninsky et a14
in their study of two aspirin-treated patients. It also was
useful in the group of patients with prolonged BT who had no
alterations in platelet function tests that could explain their
deranged primary hemostasis (vascular abnormalities?
unidentified platelet dysfunction?). As for cirrhotics, these
effects of DDAVP might be exploited when surgical proce-
dures must be carried out and a shortening of the BT must be
obtained rapidly, but clinical experience is needed to validate
this hypothesis. There is little justification for giving
DDAVP to patients with thrombasthenia, in agreement with
Kobrinsky et al,4 or to those with severe thrombocytopenia
because the BT was not shortened. Unlike Kobrinsky, we did
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